Dianthus Therapeutics
DNTH
95 hedge funds and large institutions have $248M invested in Dianthus Therapeutics in 2020 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 31 increasing their positions, 23 reducing their positions, and 3 closing their positions.
767% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 3
765% more capital inflows, than outflows
Capital inflows: $52.1M | Capital outflows: $6.02M
35% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 23
32% more funds holding
Funds holding: 72 → 95 (+23)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.37% less ownership
Funds ownership: 70.55% → 70.18% (-0.37%)
97% less call options, than puts
Call options by funds: $4K | Put options by funds: $117K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
+$5.28M |
| 2 |
Eventide Asset Management
Boston,
Massachusetts
|
+$5.02M |
| 3 |
AG
Artal Group
Luxembourg
|
+$3.96M |
| 4 |
EcoR1 Capital
San Francisco,
California
|
+$3.96M |
| 5 |
CVI Holdings
Wilmington,
Delaware
|
+$3.65M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$3.38M |
| 2 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
-$581K |
| 3 |
Marshall Wace North America
New York
|
-$435K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$358K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$200K |
DNTH Hedge Fund Activity: Q2 2020 in Review
95 of the 4,890 institutional investors tracked by Wall St. Rank reported a position in Dianthus Therapeutics (DNTH) for Q2 2020, worth a combined $248M — up 42% from $174M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new DNTH positions and 3 closed out — a net gain of 23 holders — while 31 added to existing stakes and 23 trimmed.
The largest buyer was UBS AM, opening a new position worth an estimated $5.28M. The largest seller was Opaleye Management, cutting an estimated $3.38M.
- 95 institutional investors held Dianthus Therapeutics (DNTH) as of Q2 2020, up from 72 in Q1 2020.
- Funds reported $248M of Dianthus Therapeutics stock for Q2 2020, up 42% quarter-over-quarter.
- 26 funds opened new Dianthus Therapeutics positions in Q2 2020 and 3 closed out, a net change of +23 holders.
- The largest Dianthus Therapeutics buyer in Q2 2020 was UBS AM, an estimated $5.28M added.
- The largest Dianthus Therapeutics seller in Q2 2020 was Opaleye Management, an estimated $3.38M sold.
Based on aggregated 13F filings for Q2 2020.